1.220 articles found

Long-term oral glucocerebrosidase activator reduces soluble α-synuclein oligomer accumulation in Parkinsonian LRRK2 mutant mouse brain.

Choi ZY, Liu H, Chang EE, Pang SY, Luo IL, Ruan Y, Wang Q, Malki Y, Zhang SX, Weng KY, Lau BW, Ng RC, Zhang Z, Ho SL, Ho PW.

NPJ Parkinsons Dis · 2025-12-12

DOI: 10.1038/s41531-025-01205-7PMID: 41388030

LRRK2 as a Potential Disease-Modifying Target in Sporadic Parkinson's Disease.

Lang AE, Hauser RA, Kalia LV, Hersh B, Berger Z, Arenas RL, Paisan-Ruiz C, Fraser K, Jennings D, Kluss JH, Huntwork-Rodriguez S, Henry AG, Greenamyre JT.

Mov Disord · 2025-12-12

DOI: 10.1002/mds.70100PMID: 41388619

LRRK2-Related Parkinson Disease

Wise A, Raymond D, Saunders-Pullman R.

· 2025-12-04

PMID: 20301387

Inflammatory stress on induced neurons carrying Parkinson's disease‐associated LRRK2 Mutations

Torrellas J, Chairmandurai A, Mamais A, LaVoie M, Chakrabarty P.

Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025-12-01

Synergistic Modulation of GTPase Hydrolysis and mTORC1 Activity in LRRK2-G2019S Parkinson’s Disease

Check source for author details

Innovation in aging · 2025-12-01

Motor response in monogenic LRRK2 parkinson's disease after deep brain stimulation: A systematic review and meta-analysis.

Ar Rochmah M, Subagya S, Wibowo S, Gofir A, Setyopranoto I, Wibisono DP, Nugroho DB.

Med J Malaysia · 2025-12-01

PMID: 41451724

Targeting the <i>LRRK2 G2019S</i> Mutation Found in Parkinson's Disease: Efficiency of Biosynthesized Solid Lipid Nanoparticles for Therapeutic siRNA-Mediated Gene Therapy.

Jagaran K, Singh M.

Front Biosci (Elite Ed) · 2025-12-01

DOI: 10.31083/fbe44344PMID: 41504091

Cellular and Extracellular MicroRNA Dysregulation in LRRK2-Linked Parkinson's Disease.

Knab F, Lee JH, Nirujogi R, Menden K, Braunger L, Logarnudi L, Riebenbauer B, Isik FB, Rajkumar AP, Czemmel S, Fitzgerald J, Gasser T, Gloeckner CJ.

Mol Neurobiol · 2025-11-27

DOI: 10.1007/s12035-025-05379-2PMID: 41298996

Soluble immune factor profiles in blood and CSF associated with LRRK2 mutations and Parkinson's disease.

Jaffery R, Zhao Y, Ahmed S, Schumacher JG, Ahn J, Shi L, Wang Y, Tan Y, Zhang J, Chen K, Tawbi H, Wang J, Schwarzschild MA, Peng W, Chen X.

NPJ Parkinsons Dis · 2025-11-27

DOI: 10.1038/s41531-025-01215-5PMID: 41309625

Absence of the <i>LRRK2</i> mutation in Emirati Parkinson's disease patients in contrast to other Arab populations.

Metta V, Soorajkumar A, Loney T, Nassir N, Chaudhuri KR, Uddin MJ, Benamer HTS.

Front Aging Neurosci · 2025-11-26

DOI: 10.3389/fnagi.2025.1676115PMID: 41383818

Interferon gamma stimulates coordinated changes in LRRK2, GCase, and cathepsin activities in idiopathic and genetic Parkinson's disease monocytes.

Hughes LP, Wallings RL, Agin-Liebes J, Alcalay RN, Garrido A, Tansey MG, Dzamko N.

NPJ Parkinsons Dis · 2025-11-26

DOI: 10.1038/s41531-025-01185-8PMID: 41298592

Protective or Pathogenic? Kinase activity and the neurodevelopmental origins of G2019S LRRK2-Associated Parkinson's disease.

Gatto EM, Espay AJ, Espindola M, Da Prat G, Kauffman MA.

Parkinsonism Relat Disord · 2025-11-25

DOI: 10.1016/j.parkreldis.2025.108133PMID: 41344986